Early data from the phase 1 trial (NCT05651932) of the MMSET/NSD2 inhibitor gintemetostat (KTX-1001) revealed that the agent was tolerable and produced encouraging antitumor activity in a heavily pretreated population of patients with relapsed…
Gintemetostat Shows Early Activity and Manageable Safety in Triple-Class Refractory Multiple Myeloma
